Matt Browne

Cooley advised AttackIQ, a leading vendor of adversarial exposure validation solutions, on its acquisition of assets from DeepSurface Security, a security posture management and vulnerability prioritization company. Partner Matt Browne led the Cooley team advising AttackIQ.

Cooley advised Cortica, a leading provider of advanced neurological therapies for children with autism and other developmental differences, on its $80 million financing round, co-led by Morgan Health and Nexus NeuroTech Ventures.

Cooley advised Mission Secure, a company focused on providing asset discovery for operational technology devices, on its sale to ServiceNow. Partner Matt Browne led the Cooley team advising Mission Secure.

Cooley advised TriSalus Life Sciences, an oncology company integrating its novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreatic tumors, on the closing of its previously announced exchange offer and consent solicitation for special purpose acquisition company warrants. Partner Matt Browne led the Cooley team advising TriSalus.

Cooley advised TriSalus Life Sciences, an oncology company integrating its novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreatic tumors, on the closing of a debt financing facility for up to $50 million with OrbiMed. Partners Mischi a Marca and Matt Browne led the Cooley team advising TriSalus.